Story perspectives

Wheeler Bio Partners with MindImmune to Combat Alzheimer’s

9/18/2025

Summary

Story summary

Wheeler Bio and MindImmune Therapeutics are collaborating to develop MITI-101, a monoclonal antibody targeting neuroinflammation to prevent Alzheimer’s disease.
They will use Wheeler Bio's ModularCMC platform for process development and cGMP drug manufacturing.
MITI-101 aims to block CD11c+ immune cell recruitment to the brain, addressing a critical aspect of neuroinflammation in Alzheimer’s.
The partnership highlights a commitment to innovative Alzheimer’s treatments for unmet medical needs.
Specific terms and timeline of the collaboration are not disclosed.

1 of 1

Story summary

Wheeler Bio and MindImmune Therapeutics are collaborating to develop MITI-101, a monoclonal antibody targeting neuroinflammation to prevent Alzheimer’s disease.
They will use Wheeler Bio's ModularCMC platform for process development and cGMP drug manufacturing.
MITI-101 aims to block CD11c+ immune cell recruitment to the brain, addressing a critical aspect of neuroinflammation in Alzheimer’s.
The partnership highlights a commitment to innovative Alzheimer’s treatments for unmet medical needs.
Specific terms and timeline of the collaboration are not disclosed.